Literature DB >> 31129384

Secondary haemophagocytic lymphohistiocytosis due to checkpoint inhibitor therapy.

Collin K Chin1, Sara Hall1, Celia Green2, Guy Van Hazel3, Dominic Spagnolo4, Chan Yoon Cheah5.   

Abstract

Mesh：

Substances：

Year:  2019        PMID： 31129384     DOI： 10.1016/j.ejca.2019.04.026

Source DB:  PubMed          Journal:  Eur J Cancer        ISSN： 0959-8049            Impact factor:   9.162


× No keyword cloud information.
  3 in total

1.  Secondary hemophagocytic lymphohistiocytosis due to nivolumab/ipilimumab in a renal cell cancer patient-A case report.

Authors:  Adeel Masood; Ahsan Wahab; Tanya Clifford; Eric J Weaver; Hamid Ehsan; Walid El Ayass
Journal:  Clin Case Rep       Date:  2021-12-05

Review 2.  Hemophagocytic Lymphohistiocytosis Secondary to Immune Checkpoint Inhibitor Therapy.

Authors:  Pramuditha Rajapakse; Haripriya Andanamala
Journal:  World J Oncol       Date:  2022-04-28

3.  Hemophagocytic lymphohistiocytosis in two patients following treatment with pembrolizumab: two case reports and a literature review.

Authors:  Yanqiu Wei; Wei He; Wei Sun; Chaojie Wu; Denghua Ren; Xinmin Wang; Mingshun Zhang; Mao Huang; Ningfei Ji
Journal:  Transl Cancer Res       Date:  2022-08       Impact factor: 0.496
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.